Clinical trial
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients…
NCT00454636 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00454636 |
|---|---|
| Title | A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. |
| Official title | Open Label, Phase II Study of Capecitabine (Xeloda®) as Fluoropyrimidine of Choice in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer Suitable for Treatment With a Fluoropyrimidine-Based Regimen |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | Cisplatin, Capecitabine, Epirubicin, Oxaliplatin, Docetaxel |
| Enrollment | 158 |
| Start date | Mar 1, 2007 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Apr 2, 2007 |
| Last update posted | Sep 29, 2016 |
| Countries | Spain |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: